Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a study of the safety and effectiveness of Trametinib treatment in patients who have
received successful endoscopic submucosal resection of a Stage I gastric cancer.